Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment

Investigators in the United States have developed a risk score to predict which people living with HIV have the highest risk of developing chronic kidney disease.

Published
31 March 2014
By
Michael Carter
Heart attack link to abacavir persists in D:A:D study

The nucleoside (NRTI) drug abacavir (Ziagen also in Kivexa/Epzicom) continues to be associated with a near-doubling of the risk of a heart attack, according to the latest

Published
14 March 2014
By
Gus Cairns
Raltegravir has the edge over two protease inhibitors in three-drug comparison study

In a head-to-head comparison of three drugs presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) on Wednesday, the integrase inhibitor raltegravir (Isentress) proved to

Published
07 March 2014
By
Gus Cairns
ART use not linked to advanced kidney disease in 35,000 with HIV

Neither current nor recent use of tenofovir or any other antiretroviral therapy (ART) predicted advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) in a study or more than 35,000 adults with HIV infection.

Published
12 February 2014
From
International AIDS Society
HIV increases fracture risk, say Danes

HIV infection increases the risk of fractures, Danish investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The case controlled study used data

Published
04 February 2014
By
Michael Carter
What ‘Dallas Buyers Club’ got wrong about the AIDS crisis

'Tis the season for Oscar bait, and this year, "Dallas Buyers Club" looks set to get at least a few nominations. The movie stars Matthew McConaughey as Ron Woodroof, a Dallas man who contracts HIV in 1985, when the diagnosis was a death sentence. But it risks leaving a false impression of that period in the history of HIV/AIDS, and in particular of the role of AZT.

Published
11 December 2013
From
Washington Post
Unusual and rare complication described in San Francisco

Doctors in San Francisco have reported an unusual and rare finding—an apparently harmless but disfiguring condition called cutis verticis gyrata (CVG) on the heads of four HIV-positive men. In CVG, the skin on the head becomes raised in parts and depressed in others, forming ridges and furrows.

Published
09 December 2013
From
CATIE
Differing Effects of Low- and High-Fat Meals on New Raltegravir Formulation

A high-fat meal affected levels of a reformulated raltegravir tablet less than a low-fat meal, according to results of a three-period study in healthy volunteers [1]. One aim of this trial and other ongoing research is to develop a raltegravir formulation that can be dosed once daily.

Published
30 October 2013
From
NATAP
Dual therapy with Kaletra and 3TC works well regardless of viral load

A dual combination of lopinavir/ritonavir (Kaletra or Aluvia) plus 3TC (lamivudine, Epivir) as first-line therapy produced good virological suppression regardless of baseline viral load and was well tolerated

Published
20 October 2013
By
Liz Highleyman
GSK1265744 rapidly suppresses HIV and appears safe at selected dose

The experimental HIV integrase inhibitor GSK1265744 demonstrated rapid and potent antiviral activity and good tolerability for treatment-naive people in the LATTE study, according to a report at

Published
20 October 2013
By
Liz Highleyman
← First12345...69Next →

Filter by country